No Data
Shanghai Medicilon Inc. (688202.SH): The first share buyback of 0.1582 million shares.
Gelonghui reported on April 22 that Shanghai Medicilon Inc. (688202.SH) announced that on April 22, 2025, the company repurchased 158,194 shares through centralized bidding, which accounted for 0.12% of the company's total share capital. The highest Fill Price was 28.35 yuan per share, the lowest Fill Price was 27.89 yuan per share, and the total transaction amount was 4,456,442.14 yuan (excluding stamp duty, trading commissions, and other transaction fees).
Medici: Medici: 2024 Annual Report Summary
Medici: Medici: Annual Report 2024
Medici: 2024 Annual Report
Medici: 2024 Annual Report Summary
Shanghai Medicilon Inc.'s revenue in 2024 declined by over 20%, with losses further expanding.
① Affected by multiple factors such as the slowdown in investment and financing in the Industry, intensified market competition, and contraction in domestic market demand, Shanghai Medicilon Inc. is expected to continue expanding its losses to 0.331 billion yuan in 2024; ② By region, the domestic market is heavily impacted by the reduction in R&D investment from local pharmaceutical companies and price wars, becoming the main drag on performance; the Overseas market, although maintaining growth, has seen increased costs due to new experimental facility investments, squeezing profit margins.
Is Shanghai Medicilon (SHSE:688202) Using Too Much Debt?
